SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Cortistatin-29

Cat. No.:	HY-P2150
CAS No.:	1815618-17-7
Molecular Formula:	$C_{161}H_{240}N_{46}O_{41}S_2$
Molecular Weight:	3540.04
Sequence:	{Glp}-Glu-Arg-Pro-Pro-Leu-Gln-Gln-Pro-Pro-His-Arg-Asp-Lys-Lys-Pro-Cys-Lys-Asn-Phe -Phe-Trp-Lys-Thr-Phe-Ser-Ser-Cys-Lys (disulfide bridge: Cys17-Cys28)
Sequence Shortening:	{Glp}-ERPPLQQPPHRDKKPCKNFFWKTFSSCK (disulfide bridge: Cys17-Cys28)
Target:	Somatostatin Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cortistatin-29 is a neuropeptide. Cortistatin-29 alleviates neuropathic pain. Cortistatin-29 binds all somatostatin (SS) receptor subtypes with high affinity and shows IC_{50} values of 2.8 nM, 7.1 nM, 0.2 nM, 3.0 nM, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin-29 shows anti-fibrotic effects[1][2][3][4].
IC_{50} & Target	SSTR1 2.8 nM (IC_{50}) SSTR2 7.1 nM (IC_{50}) SSTR3 0.2 nM (IC_{50}) SSTR4 3.0 nM (IC_{50}) SSTR5 13.7 nM (IC_{50})
In Vivo	Cortistatin 29 (1-2 μg) alleviates chronic neuropathic pain in mouse[1]. Cortistatin 29 (1 nmol/mouse; i.p.; three times weekly) shows anti-fibrotic effects in mouse[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	20-24 g body weight, 8-12 weeks-old mice[1]
Dosage:	1 μg in 20 μL for s.c.; 2 μg in 200 μL for i.p.; 20 ng in 10 μL for i.t.
Administration:	Every other day for 12 days
Result:	Ameliorated hyperalgesia and allodynia, regulated the nerve damageinduced hypersensitization of primary nociceptors, inhibited neuroinflammatory responses, and enhanced the production of neurotrophic factors both at the peripheral and central levels.

REFERENCES

[1]. Falo CP, et al. The Neuropeptide Cortistatin Alleviates Neuropathic Pain in Experimental Models of Peripheral Nerve Injury. Pharmaceutics. 2021 Jun 24;13(7):947.

[2]. Baranowska B, et al. Direct effect of cortistatin on GH release from cultured pituitary cells in the rat. Neuro Endocrinol Lett. 2006 Feb-Apr;27(1-2):153-6.

[3]. Spier AD, et al. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Brain Res Rev. 2000 Sep;33(2-3):228-41.

[4]. Benitez R, et al. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic- and cholestatic-induced liver injury. Br J Pharmacol. 2022 May;179(10):2275-2296.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA